Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

MEI Pharma Inc (MEIP) USD0.00000002

Sell:$2.54 Buy:$2.55 Change: $0.06 (2.31%)
NASDAQ:0.80%
Market closed |  Prices as at close on 20 June 2019 | Switch to live prices |
Sell:$2.54
Buy:$2.55
Change: $0.06 (2.31%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 20 June 2019 | Switch to live prices |
Sell:$2.54
Buy:$2.55
Change: $0.06 (2.31%)
Market closed |  Prices as at close on 20 June 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Contact details

Address:
3611 Valley Centre Dr Ste 500
SAN DIEGO
92130-3324
United States
Telephone:
+1 (858) 7926300
Website:
www.meipharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MEIP
ISIN:
US55279B2025
Market cap:
$185.36 million
Shares in issue:
71.29 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Christine White
    Independent Chairman of the Board
  • Daniel Gold
    President, Chief Executive Officer, Director
  • Brian Drazba
    Chief Financial Officer, Secretary
  • David Urso
    Chief Operating Officer, Senior Vice President - Corporate Development, General Counsel
  • Robert Mass
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.